{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:31:44Z","timestamp":1793763104676,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KUL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejpb.2026.115258","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:04:38Z","timestamp":1791561878000},"page":"115258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mechanistic insights into the influence of aqueous ethanolic media on the permeability of HPMC phthalate-based isolated films"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-0107","authenticated-orcid":false,"given":"Naitik","family":"Jariwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentina-Maria","family":"Preda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9221-421X","authenticated-orcid":false,"given":"Anne","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Provinciael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1123-1907","authenticated-orcid":false,"given":"Kurt","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Van","family":"den Mooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115258_b0005","unstructured":"U.S. Food and Drug Administration., Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Post approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation, Tel, 1997. http:\/\/www.fda.gov\/cder\/guidance\/index.htm."},{"key":"10.1016\/j.ejpb.2026.115258_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/s41120-017-0014-9","article-title":"A review of in vivo and in vitro aspects of alcohol-induced dose dumping","volume":"3","author":"D\u2019Souza","year":"2017","journal-title":"AAPS Open"},{"key":"10.1016\/j.ejpb.2026.115258_b0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0091270011403740","article-title":"Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules","volume":"52","author":"Johnson","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115258_b0020","unstructured":"Purdue Pharma L.P., Citizen Petition Regarding In Vitro Alcohol Testing of Modified-Release Oral Dosage Forms Containing Opioid Active Ingredients, (2007). https:\/\/www.regulations.gov\/document\/FDA-2007-P-0003-0004 (accessed July 3, 2026)."},{"key":"10.1016\/j.ejpb.2026.115258_b0025","unstructured":"U.S. Food and Drug Administration., Information for Healthcare Professionals: Hydromorphone Hydrochloride Extended-Release Capsules (marketed as Palladone), 2005."},{"key":"10.1016\/j.ejpb.2026.115258_b0030","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/03639040701377292","article-title":"The effect of ethanol on the release of opioids from oral prolonged-release preparations","volume":"33","author":"Walden","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpharm.2008.04.035","article-title":"Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol","volume":"360","author":"Fadda","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2010.07.031","article-title":"In vitro dissolution of oral modified-release tablets and capsules in ethanolic media","volume":"398","author":"Smith","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2026.126940","article-title":"Effect of drug solubility, polymer, and filler on drug release from modified-release matrix tablets in hydroethanolic media","volume":"698","author":"Heinrich","year":"2026","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2006.09.055","article-title":"Influence of ethanol on aspirin release from hypromellose matrices","volume":"332","author":"Roberts","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/03639040801929240","article-title":"Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments","volume":"34","author":"Traynor","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejpb.2014.02.008","article-title":"The design of controlled-release formulations resistant to alcohol-induced dose dumping - a review","volume":"87","author":"Jedinger","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2013.04.001","article-title":"Ethanol-resistant polymeric film coatings for controlled drug delivery","volume":"169","author":"Rosiaux","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115258_b0070","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s11095-025-03968-3","article-title":"Development of alcohol-resistant extended-release formulations: regulatory considerations and formulation strategies","volume":"42","author":"Ji","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115258_b0075","unstructured":"European Medicines Agency, Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms, London, 2014. https:\/\/www.ema.europa.eu\/en\/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms-scientific-guideline (accessed July 3, 2026)."},{"key":"10.1016\/j.ejpb.2026.115258_b0080","unstructured":"U.S. Food and Drug Administration., Center for Drug Evaluation and Research, Bioavailability Studies Submitted in NDAs or INDs-General Considerations, Guidance for Industry, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioavailability-studies-submitted-ndas-or-inds-general-considerations (accessed July 3, 2026)."},{"key":"10.1016\/j.ejpb.2026.115258_b0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/10837450.2017.1412461","article-title":"Ethanol effect on acid resistance of selected enteric polymers","volume":"24","author":"Al-Zoubi","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2026.115258_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126252","article-title":"The impact of triethyl citrate leaching from HPMC-phthalate based isolated films on film permeability and thermal properties","volume":"685","author":"Jariwala","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0378-5173(94)00102-2","article-title":"Characterization of colon-specific azo polymers: a study of the swelling properties and the permeability of isolated polymer films","volume":"111","author":"Van Den Mooter","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0100","unstructured":"European Medicines Agency, Quality of medicines: questions and answers - Part 2; Specific types of products - Need for in vitro dissolution studies with alcohol for modified-release oral products including opioid drug products, (n.d.). https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/quality-medicines-questions-answers-introduction\/quality-medicines-questions-answers-part-2 (accessed July 14, 2026)."},{"key":"10.1016\/j.ejpb.2026.115258_b0105","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5c01573","article-title":"The impact of plasticizer polarity on the permeability of hydroxypropyl methylcellulose phthalate films","author":"Jariwala","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejpb.2010.09.007","article-title":"Effect of ethanol on the water permeability of controlled release films composed of ethyl cellulose and hydroxypropyl cellulose","volume":"76","author":"Larsson","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0378-5173(86)90241-3","article-title":"Comparison and evaluation of enteric polymer properties in aqueous solutions","volume":"28","author":"Davis","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115258_b0120","unstructured":"Ltd. Shin-Etsu Chemical Co., Official Product Information-Hypromellose Phthalate NF (HPMCP): Enteric Coating Material, 2021. https:\/\/www.metolose.jp\/en\/pharmaceutical\/hpmcp.html (accessed July 3, 2026)."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:18:04Z","timestamp":1793762284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":24,"alternative-id":["S0939641126002791"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115258","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into the influence of aqueous ethanolic media on the permeability of HPMC phthalate-based isolated films","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115258"}}